Inhibrx Biosciences Reports Q3 Earnings with GAAP EPS Beat and $2 Million Revenue
Inhibrx Biosciences (INBX) reported third-quarter financial results, posting a GAAP earnings per share (EPS) of -$2.46. This figure exceeded analyst expectations by $0.06. The company also reported quarterly revenue of $2 million. As of September 30, 2026, Inhibrx maintained a strong liquidity position with $199.5 million in cash and cash equivalents. Despite the earnings beat, the stock experienced a downward movement of approximately 5.07% following the report.
